What Prenetics Global (PRE) Said on Its Q3 Earnings Call
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest and never sell or share it. See our privacy policy.
Prenetics Global (NASDAQ:PRE) reported third-quarter revenue of $64.1 million as sales of its IM8 supplement brand climbed, but widened its expected second-half adjusted EBITDA loss as it plans to spend more on customer acquisition. The company now expects an adjusted EBITDA
Directly affected
- PRE Prenetics Global
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Prenetics Global belongs to, so it often moves with news about it.
- ZLAB Zai Lab+3.6% 10d
Zai Lab is a peer of Prenetics Global in pharmaceutical preparations; rivals often move on the same news.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and is a peer of Prenetics Global in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson is a peer of Prenetics Global in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+12.0% 30d
AbbVie is a peer of Prenetics Global in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.5% 30d
Merck is a peer of Prenetics Global in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| PRE | +7.24% | +0.48% | base | -41.13% | after close | after close | after close |
| XLV | +2.00% | +1.95% | base | -1.44% | after close | after close | after close |
| ZLAB | +12.32% | +4.59% | base | -4.93% | after close | after close | after close |
| LLY | +1.56% | +2.06% | base | -1.28% | after close | after close | after close |
| JNJ | +0.58% | +2.60% | base | -0.98% | after close | after close | after close |
| ABBV | +0.73% | +0.77% | base | -1.51% | after close | after close | after close |
| MRK | +2.66% | +3.05% | base | -3.34% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
What Prenetics Global (PRE) Said on Its Q3 Earnings Call Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | -1.51% | still updating |
| ABBV | three days earlier | +0.77% | final price |
| ABBV | five days earlier | +0.73% | final price |
| JNJ | that day | -0.98% | still updating |
| JNJ | three days earlier | +2.60% | final price |
| JNJ | five days earlier | +0.58% | final price |
| LLY | that day | -1.28% | still updating |
| LLY | three days earlier | +2.06% | final price |
| LLY | five days earlier | +1.56% | final price |
| MRK | that day | -3.34% | still updating |
| MRK | three days earlier | +3.05% | final price |
| MRK | five days earlier | +2.66% | final price |
| PRE | that day | -41.13% | still updating |
| PRE | three days earlier | +0.48% | final price |
| PRE | five days earlier | +7.24% | final price |
| XLV | that day | -1.44% | still updating |
| XLV | three days earlier | +1.95% | final price |
| XLV | five days earlier | +2.00% | final price |
| ZLAB | that day | -4.93% | still updating |
| ZLAB | three days earlier | +4.59% | final price |
| ZLAB | five days earlier | +12.32% | final price |
Congressional trades in the stocks in this story
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 15 days before publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 29 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 75 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 42 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 49 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 54 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 42 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 65 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 75 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “What Prenetics Global (PRE) Said on Its Q3 Earnings Call” looks
12 out of 100Price not final
“What Prenetics Global (PRE) Said on Its Q3 Earnings Call” scores 12 out of 100. The score uses 1 source. The price is not final yet.